Enliven Therapeutics reported a third quarter 2026 net loss of US$27.7 million and a basic loss per share of US$0.36, with nine month losses reaching US$83.82 million and a basic loss per share of US$...
Source LinkEnliven Therapeutics reported a third quarter 2026 net loss of US$27.7 million and a basic loss per share of US$0.36, with nine month losses reaching US$83.82 million and a basic loss per share of US$...
Source Link
Comments